Drugs / AdCh3NSmut1
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02568332 | Jul 2015 → Jan 2017 | hepatitis C virus infection | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT02362217 | Oct 2014 → Aug 2016 | HIV infectious disease, hepatitis C virus infection | University of Oxford | Completed | No outcome recorded |
| Phase 1 | NCT01296451 | Dec 2010 → Jan 2016 | hepatitis C virus infection | ReiThera Srl | Completed | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT01436357 | Mar 2012 → May 2018 | hepatitis C virus infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdCh3NSmut1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02362217 ↗ |
| Modality | Vaccine | “AdCh3NSmut1 and MVA-NSmut HCV vaccine” NCT01436357 ↗ |
| Route | Intramuscular | “vaccinated via the intramuscular route” PMID 30713538 ↗ Jan 2019 |